Compounding pharmacies in Louisiana

Verified compounding pharmacies serving Louisiana

Who regulates compounding pharmacies in Louisiana

The Louisiana Board of Pharmacy regulates pharmacies under the Louisiana Pharmacy Practice Act (La. R.S. Title 37, chapter 14) and its rules in Louisiana Administrative Code Title 46, Part LIII. Louisiana has no separate state bulks list, so peptide eligibility follows the federal 503A framework (approved drug component, USP or NF monograph, or FDA 503A bulks list), and the Board's executive director has stated publicly that compounders may only use bulk substances that meet the federal requirements. Under La. R.S. 37:1232, a pharmacy outside Louisiana that does business in Louisiana must hold a Louisiana pharmacy permit, disclose its officers and pharmacist in charge, submit its latest home-state, FDA, and DEA inspection reports before permitting and every later report after, and keep Louisiana prescription records readily retrievable. The Board's compounding rules are LAC 46:LIII, Chapter 25, Subchapter C (sections 2531 to 2535). Section 2535 requires compounding to comply with the federal Food, Drug and Cosmetic Act, 21 CFR, and all relevant USP-NF chapters; sterile preparations compounded on a patient-specific prescription must meet section 503A and USP chapter 797, and nonsterile ones section 503A and USP chapter 795. A pharmacy must notify the Board and receive approval before starting sterile compounding, products removed from the market for safety may not be used to compound for humans, and copies of commercial products (same active ingredient, strength within 10 percent, same route) require a documented prescriber determination of a clinically significant difference unless the product is discontinued, on the FDA shortage list, or temporarily unavailable. Act 374 of 2026 (Senate Bill 253), signed May 22, 2026 and effective August 1, 2026, enacts La. R.S. 37:23.5. It bars any professional or occupational licensing board from prohibiting a prescriber from providing patients with peptides shipped from an FDA-registered 503B outsourcing facility that complies with 21 U.S.C. 353b or from a 503A compounding pharmacy that complies with 21 U.S.C. 353a and applicable USP-NF chapters. It also bars boards from prohibiting a Louisiana-licensed pharmacist in a state-permitted pharmacy from compounding and dispensing peptides in compliance with 21 U.S.C. 353a and applicable USP-NF chapters. The act protects only compounding that already complies with federal law. It does not make any peptide eligible for 503A or 503B compounding. [1] [3] [4] [5] [6] [7] [9] [10] [15]

Compounded GLP-1 access in Louisiana

In spring 2023, while semaglutide was still in shortage, the Louisiana Board of Pharmacy told in-state compounders to stop compounding semaglutide made from unapproved salt forms (such as semaglutide sodium or acetate) and told out-of-state compounders not to ship such products into Louisiana; the Board's director clarified that compounding with the approved base form was not banned at the time. Since the FDA shortage allowances ended in 2025, compounded semaglutide and tirzepatide are limited to documented patient-specific needs in Louisiana as elsewhere. Telehealth weight management programs serving Louisiana patients must use a live, synchronous interaction under Act 345 of 2026. [1] [8] [9] [13]

Research use only sellers in Louisiana

Only Louisiana-permitted pharmacies, including nonresident pharmacies permitted under La. R.S. 37:1232, may dispense prescription drugs to Louisiana patients. The Louisiana Board of Pharmacy has described semaglutide salt forms sold as "research use only" as not intended for human use, and "research use only" peptides sold for injection are unapproved new drugs under federal law. [3] [9] [14]